 |
| RNA as a drug in therapy |
RNA-based drugs are changing modern medicine by shifting the focus from treating symptoms with proteins to fixing problems at their source: the genetic blueprint. This review covers the fast-moving world of RNA therapeutics, which offer an unprecedented ability to turn "on" or "off" the genes that cause disease, many of which were previously considered "undruggable." We'll break down the main types of RNA drugs, from gene-silencers like siRNA and ASOs to mRNA platforms used for protein replacement and vaccines. The success of these technologies relies on two key innovations: chemically engineering the RNA molecules for better stability and lower immunogenicity, and developing sophisticated delivery systems—especially lipid nanoparticles (LNPs)—to protect the RNA and get it into the right cells. We'll explore the latest advances, including "smart" nanocarriers and natural delivery vehicles like exosomes. Finally, this review highlights how RNA therapy is merging with advanced data science. The combination of multi-omics, AI, and the emerging science of the epitranscriptome (the chemical modifications on RNA) is ushering in a new era of programmable, personalized medicine.
Introduction: The RNA Renaissance
For decades, drug
development has focused on designing small molecules or antibodies to block
disease-causing proteins. While incredibly successful, this approach can only
target proteins with specific, accessible shapes. A vast number of diseases are
caused by proteins that are considered "undruggable."
RNA therapeutics flip the script by intervening one step earlier, targeting the
RNA instructions before a problematic protein is ever made. This gives them the
power to modulate virtually any gene with incredible specificity. The stunning
success of the mRNA COVID-19 vaccines provided a global proof-of-concept,
sparking a renaissance in RNA research and turning these platforms from a
promising idea into a clinical reality.
This review explores
the diverse toolkit of RNA therapies:
·
Gene
Silencers: Agents like small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) that find and destroy
specific RNA messages to shut down the production of harmful proteins.
·
Protein
Producers: Messenger RNAs (mRNAs) that give cells the temporary
instructions to produce beneficial proteins, such as vaccine antigens or
functional enzymes missing in genetic disorders.
·
Catalytic
Cutters: Nucleic acid enzymes
like DNAzymes that can catalytically slice up target RNA
molecules.
The journey of these
drugs to the clinic is a story of co-evolution. The fragile RNA molecule had to
be re-engineered to be more drug-like, while a protective delivery vehicle had
to be invented to carry it. This has been solved through two parallel streams
of innovation: chemical modification of the RNA to
make it stable and "invisible" to the immune system, and the
development of advanced nanocarriers to shield the
RNA and guide it to its target.
Today, a third pillar
supports this revolution: the integration of these platforms with powerful data
analytics. Multi-omics technologies (like single-cell and spatial
transcriptomics) are giving us a high-definition map of disease, while AI and machine learning are helping us find new drug
targets and design better therapies, paving the way for true precision
medicine.
The Gene Regulation Toolkit 🧰
The core strength of
many RNA therapies is their ability to precisely control gene expression.
Different modalities use distinct biological pathways to silence or modulate
disease-causing genes.
Small Interfering RNAs (siRNAs): Molecular Scissors for Gene Silencing
siRNAs tap into a
natural cellular process called RNA interference (RNAi).
These drugs are short, double-stranded RNA molecules designed to perfectly
match a target mRNA. Once inside a cell, the siRNA is loaded into a protein complex
called RISC. The RISC complex discards one strand and uses the
remaining "guide" strand to find the matching mRNA. When it finds its
target, an enzyme within RISC called Argonaute-2 acts
like a pair of molecular scissors, cleaving the mRNA and marking it for
destruction. This catalytic process—where one siRNA can lead to the destruction
of many mRNAs—makes it incredibly potent and specific. A major challenge is
getting the siRNA into the cell's cytoplasm without it getting trapped.
Innovative solutions include directly attaching siRNA to molecules that can
slip across the cell membrane or using the GalNAc ligand, a
"homing signal" that directs the siRNA specifically to liver cells.
Antisense Oligonucleotides (ASOs): The Swiss Army Knife of Gene Modulation
ASOs are
single-stranded DNA or RNA molecules that are true multi-taskers, offering a
wider range of actions than siRNA.
·
Search
and Destroy: "Gapmer"
ASOs can bind to an mRNA target and recruit a natural enzyme called RNase H1 to come and degrade it.
·
Splicing
Modulation: ASOs can bind to
pre-mRNA and influence how it's spliced together. This can be used to force the
cell to "skip" a mutated part of a gene (as in therapies for Duchenne
muscular dystrophy) or to include a missing part (the mechanism behind Nusinersen, a treatment for spinal muscular atrophy).
·
Translational
Blocking: An ASO can act as a
physical roadblock, binding to an mRNA and preventing the cell's protein-making
machinery from even starting its job.
The success of ASOs is
built on decades of chemical engineering to improve their stability and reduce
toxicity, with newer chemistries like serinol nucleic acids (SNAs)
showing even better safety and efficacy in preclinical models.
Catalytic Nucleic Acids: DNAzymes as Tiny Engines
DNAzymes are single-stranded DNA molecules that act
like enzymes. The "10-23" DNAzyme is engineered with a catalytic core
flanked by two binding arms that recognize a specific mRNA target. Once bound,
the core cleaves the mRNA. Because it's a catalyst, a single DNAzyme can find
and destroy multiple mRNA targets, unlike ASOs which work one-to-one. A recent
breakthrough is the creation of "ASO-like DNAzymes,"
which incorporate the chemical modifications that make ASOs so stable and effective.
This hybrid approach created a more potent and durable drug, showcasing a
powerful trend in the field: mixing and matching the best features from
different platforms to build superior therapeutics.
Building Proteins on Demand with mRNA
While other modalities
focus on silencing genes, mRNA therapeutics work by adding
a new set of instructions, telling the cell to produce a specific protein. This
has transformed vaccine development and holds huge promise for treating genetic
diseases.
The Architecture of a Therapeutic mRNA
A synthetic mRNA is
engineered from end to end for maximum performance and minimum side effects.
1.
5'
Cap: A modified nucleotide
at the start of the chain that acts as the "start here" signal for
protein synthesis and protects the mRNA from being degraded. Advanced caps like
CleanCap M6 are more stable, leading to longer-lasting
protein production.
2.
Untranslated
Regions (UTRs): Non-coding sequences
at the beginning and end that control the mRNA's stability and how efficiently
it's translated.
3.
Open
Reading Frame (ORF): The core sequence
that codes for the desired protein. It's optimized by swapping out rare codons
for more common ones and, crucially, by replacing the standard uridine
nucleotide with a modified version like N1-methylpseudouridine (m1Ψ). This "stealth" modification,
pioneered by Karikó and Weissman, hides the mRNA from the immune system and
boosts protein production.
4.
Poly(A)
Tail: A long tail of
adenine bases at the end that protects the mRNA and helps initiate translation.
mRNA Vaccines: How They Work
The success of the
COVID-19 mRNA vaccines stems from their ability to generate a powerful,
two-pronged immune response. After injection, the LNP-packaged mRNA is taken up
by cells, which then use the instructions to produce the viral antigen (e.g.,
the spike protein). This internally-produced antigen is presented to the immune
system in two ways:
·
It activates CD8+ T cells (the "killers") to find and
destroy any cells infected with the actual virus.
·
It activates CD4+ T cells (the "helpers") which in turn
signal B cells to produce a flood of potent, long-lasting
neutralizing antibodies.
This ability to
stimulate both cellular and humoral immunity is a key advantage of the mRNA
platform.
The Epitranscriptome Connection
Beyond vaccines, mRNA
can be used for protein replacement therapies and even gene editing. The
development of mRNA is deeply connected to epitranscriptomics—the
study of natural chemical modifications on RNA. The initial breakthrough of
using m1Ψ came directly from understanding how our own
cells modify RNA. The field is now entering a new phase where this knowledge is
being used for hyper-specific targeting. For example, by understanding which
codons are translated most efficiently in brain cells versus liver cells,
scientists can design an mRNA's sequence to express a protein preferentially in
one organ over another, offering a new layer of precision control.
The Delivery Dilemma: Getting RNA Drugs to the Right Place
An RNA drug is only as
good as its delivery system. The carrier must protect the fragile RNA, get it
to the target tissue, and help it enter the cell.
Lipid Nanoparticles (LNPs): The Clinical Gold Standard
LNPs are the most
successful delivery system for RNA, forming the basis of approved siRNA and
mRNA drugs. The four-part recipe is key:
·
Ionizable
Lipid: The workhorse. It's
positively charged to bind RNA during manufacturing but nearly neutral in the
blood to reduce toxicity. Inside the acidic environment of a cell's endosome,
it becomes charged again, helping to break the compartment open and release the
RNA.
·
Helper
Phospholipid & Cholesterol: Provide structural stability.
·
PEG-Lipid: Forms a "stealth" coating to help
the LNP evade the immune system and circulate longer.
Standard LNPs have a
natural tendency to end up in the liver. A major goal is to break this pattern.
Recent breakthroughs have shown that by changing the shape
of the ionizable lipid (e.g., using dendron-like structures), it's possible to
shift delivery away from the liver and toward other organs like the spleen.
Other Delivery Platforms
·
Polymers
and Conjugates: Cationic polymers can
wrap RNA into nanoparticles, while direct conjugation involves attaching a
targeting molecule (like GalNAc for the liver) directly to the RNA, creating a
minimalist drug.
·
Biogenic
Carriers: Extracellular vesicles (EVs) or exosomes are "nature's nanoparticles." Using
these naturally occurring vesicles for delivery offers excellent
biocompatibility and the ability to cross biological barriers like the
blood-brain barrier (BBB).
·
"Smart"
Delivery Systems: The most advanced
systems are designed to respond to external triggers. One futuristic example is
an ultrasound-responsive "cluster bomb." In this
system, tiny siRNA nanoparticles are loaded inside larger nanodroplets. When
focused ultrasound is applied to a target like the brain, the nanodroplets
vaporize, locally opening the BBB and releasing the therapeutic nanoparticles
directly at the site of action. This "divide and conquer" strategy is
a glimpse into the future of overcoming biology's toughest barriers.
Building a Better Drug: Engineering and Editing RNA
The properties of the
RNA molecule itself are just as important as its delivery vehicle. Molecular
engineering transforms fragile RNA into a robust drug.
Chemical Modifications for Drug-Like Properties
Unmodified RNA is
quickly destroyed by enzymes and can trigger a strong immune reaction. Chemical
modifications solve these problems:
·
Phosphate
Backbone: Replacing an oxygen
with a sulfur atom creates a phosphorothioate (PS)
linkage, which is the most common way to make an oligonucleotide resistant to
degradation.
·
Sugar
Moiety: Adding groups like 2'-O-Methyl (2'-OMe) or 2'-Fluoro (2'-F) to
the ribose sugar increases stability and binding affinity. These are standard
in ASOs and siRNAs.
·
Novel
Chemistries: New platforms like serinol nucleic acids (SNAs) are constantly being
developed to further improve safety and efficacy.
The Epitranscriptome: The New Frontier of Therapeutic Control
The epitranscriptome is the collection of natural chemical
marks on RNA that control its function. Dysregulation of these marks is
involved in many diseases, creating a whole new class of drug targets. The
relationship between RNA drugs and the epitranscriptome is evolving rapidly:
1.
Mimicking: The field started by copying natural modifications. Using m1Ψ in mRNA vaccines to
trick the immune system is the prime example.
2.
Targeting: The next step is to target the cellular machinery that reads, writes, or
erases these marks. Small molecules that inhibit overactive "writer"
or "reader" proteins are showing promise as cancer and antiviral
therapies.
3. Editing: The ultimate goal is precision editing of the epitranscriptome. In one remarkable study of a rare genetic disorder, a disease was caused not by a faulty protein sequence, but because a mutation changed the mRNA's shape, hiding a crucial m6A modification site. The defect was corrected in two ways: with an ASO designed to unfold the RNA and re-expose the site, or with a programmable dCas13b-METTL3 "RNA editor" that could be guided to install the missing m6A mark. This represents a new paradigm: fixing disease by restoring the normal regulation of an RNA molecule, one chemical mark at a time.
|
Feature |
Small
Interfering RNA (siRNA) |
Antisense
Oligonucleotide (ASO) |
Messenger
RNA (mRNA) |
DNAzyme |
|
Structure |
Double-stranded RNA, ~21-23 bp |
Single-stranded DNA/RNA, ~15-21 nt |
Single-stranded RNA, 100s-1000s nt |
Single-stranded DNA, ~30-40 nt |
|
Mechanism |
RISC-mediated cleavage of mRNA |
Multiple: RNase H, splicing,
blocking |
Provides template for protein
translation |
Catalytic cleavage of mRNA |
|
Key
Mods |
2'-Sugar mods, PS backbone, GalNAc |
PS backbone, 2'-MOE, LNA, SNA |
5' Cap, m1Ψ nucleosides, UTRs |
PS backbone, 2'-F (in hybrids) |
|
Delivery |
LNPs, GalNAc conjugates, polymers |
Often "naked" (for CNS),
LNPs |
Lipid Nanoparticles (LNPs) |
Nanoparticles, conjugates |
|
Advantage |
High potency and specificity |
Mechanistic versatility |
Expresses any protein; rapid
platform |
Catalytic turnover |
|
Challenge |
Delivery beyond liver; endosomal
escape |
Potential for off-target effects |
Extra-hepatic delivery; stability |
In vivo stability and delivery |
The Future: AI-Driven, Personalized RNA Medicine
The RNA therapeutics
field is at an inflection point, moving from a promising concept to a clinical
reality. The next wave of innovation will be driven by integrating these drug
platforms with powerful data science.
Single-cell and spatial omics are giving us a "Google Maps" of
disease, revealing the complex ecosystems of cells in a tumor and identifying
the exact cellular interactions that lead to drug resistance or success. AI and machine learning are becoming essential tools to
find patterns in this data, discovering new drug targets and identifying robust
biomarkers that can predict which patients will respond to a given therapy.
The ultimate goal is
to create a seamless pipeline from patient-specific data to personalized drug
design. Imagine using single-cell sequencing to identify the exact cell type
driving a patient's disease, then designing an LNP with a custom targeting
ligand to deliver a precisely engineered RNA drug to that cell alone. While
significant challenges in delivery, manufacturing, and long-term safety
remain, the path forward is clear. The future of RNA medicine is one of
astonishing precision and programmability, where therapies are rapidly designed
and deployed based on a deep, data-driven understanding of an individual's
unique biology.
References
·
Han, et al., 2024,
Precision recruitment of writers and erasers to edit RNA modifications,
·
Lee, et al., 2025,
Recent Update on siRNA Therapeutics,
·
Rinaldi, et al.,
2020, Antisense Oligonucleotides: An Emerging Area in Drug Discovery and
Development,
·
Dhuri, et al., 2023,
Antisense oligonucleotides: a novel Frontier in pharmacological strategy,
·
Kim, et al., 2023,
Drug Discovery Perspectives of Antisense Oligonucleotides,
·
Bose, et al., 2025,
Revolutionizing immunization: a comprehensive review of mRNA vaccine technology
and applications,
·
Wang, et al., 2025,
Technological breakthroughs and advancements in the application of mRNA
vaccines: a comprehensive exploration and future prospects,
·
Xu, et al., 2023, A
Comprehensive Review of mRNA Vaccines,
·
Fell, et al., 2021,
Understanding mRNA vaccine technologies,
·
Zhang, et al., 2023,
Recent Advancement in mRNA Vaccine Development and Applications,
·
Subhan, et al., 2021,
infinite possibilities of RNA therapeutics,
·
Kesharwani, et al.,
2025, The new era of siRNA therapy: Advances in cancer treatment,
·
Bose, et al., 2025,
Unleashing the potential of mRNA: Overcoming delivery challenges with nanoparticles,
·
Dahlman, et al.,
2023, Recent advances in nanoparticulate RNA delivery systems,
·
Yamamoto, et al.,
2024, Chemically Modified Platforms for Better RNA Therapeutics,
·
Shin, et al., 2024,
Recent Advances and Prospects in RNA Drug Development,
·
Biopharma PEG, et
al., 2023, siRNA Drugs: Challenges and Opportunities,
·
Zhao, et al., 2024,
Antisense oligonucleotides and their applications in rare neurological
diseases,
·
Li, et al., 2023, A
promising nucleic acid therapy drug: DNAzymes and its delivery system,
·
Weng, et al., 2023,
Chemical Modifications of mRNA Ends for Therapeutic Applications,
·
Nance, et al., 2022,
The Pivotal Role of Chemical Modifications in mRNA Therapeutics,
·
Martin, et al.,
2022, Lipid nanoparticles for delivery of RNA therapeutics: Current status and
the role of in vivo imaging,
·
Zhang, et al., 2023,
Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery,
·
Guan, et al., 2022,
Recent Advances in Lipid Nanoparticles for Delivery of mRNA,
·
Mai, et al., 2024,
Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA
Delivery,
·
Turan, et al., 2024,
Advances in RNA-Based Therapeutics: Challenges and Innovations in RNA Delivery
Systems,
·
Salerno, et al.,
2017, Functional Peptides for siRNA Delivery,
·
Meade, et al., 2010,
Delivery of siRNA and other macromolecules into skin and cells using a peptide
enhancer,
·
Bio-Synthesis Inc.,
et al., 2025, Cell-penetrating peptides for the delivery of siRNA into cells,
·
Joliot, et al.,
2018, Versatility of cell-penetrating peptides for intracellular delivery of
siRNA,
·
Wang, et al., 2016,
Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating
Peptide,
·
Cho, et al., 2023,
Tissue-Specific Cell Penetrating Peptides for Targeted Delivery of Small
Interfering RNAs,
·
Koniusz, et al.,
2021, Why Extracellular Vesicles Are Attractive Vehicles for RNA-Based
Therapies?,
·
O'Brien, et al.,
2024, Therapeutic potential of RNA-enriched extracellular vesicles: The next
generation in RNA delivery via biogenic nanoparticles,
·
Stanford University,
2021, Exosome platform for tissue-specific drug delivery of mRNA or other
therapeutic cargo,
·
Mentkowski, et al.,
2024, Extracellular Vesicles: Tiny Messengers for Mighty RNA Delivery,
·
Dadashzadeh, et al.,
2023, Exosome-Based Carrier for RNA Delivery: Progress and Challenges,
·
Hu, et al., 2024,
mRNA Delivery: Challenges and Advances through Polymeric Soft Nanoparticles,
